Metraipolis › archive › dc_7b5ef9e55ebe
Cost-Effectiveness of Sacituzumab Govitecan Versus Chemotherapy in Metastatic Triple-Negative Breast Cancer in Taiwan — Europe PMC PMID:41154362
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41154362
- DOI
- 10.3390/cancers17203305
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T09:19:33.879Z
- SHA-256 of the archived text
6d5812a741773d0fcc5f0fcb411f16689e13fe5d148697506b35884f86e997c7- Stable URL of this page
https://metraipolis.com/documento/dc_7b5ef9e55ebe
How to cite
Cost-Effectiveness of Sacituzumab Govitecan Versus Chemotherapy in Metastatic Triple-Negative Breast Cancer in Taiwan — Europe PMC PMID:41154362 — Europe PMC (en), https://europepmc.org/article/MED/41154362 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7b5ef9e55ebe (Metraipolis archive dc_7b5ef9e55ebe, sha256 6d5812a741773d0fcc5f0fcb411f16689e13fe5d148697506b35884f86e997c7)
BibTeX
@misc{dc7b5ef9e55ebe,
title = {Cost-Effectiveness of Sacituzumab Govitecan Versus Chemotherapy in Metastatic Triple-Negative Breast Cancer in Taiwan — Europe PMC PMID:41154362},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41154362},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7b5ef9e55ebe; sha256 6d5812a741773d0fcc5f0fcb411f16689e13fe5d148697506b35884f86e997c7},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41154362. Agents can read the archived copy with the MCP tool read_document.